GBA mutations are associated with Rapid eye movement sleep behavior disorder

Rapid eye movement sleep behavior disorder and GBA mutations are both associated with Parkinson’s disease. The GBA gene was sequenced in idiopathic rapid eye movement sleep behavior disorder patients (n = 265), and compared to controls (n = 2240). Rapid eye movement sleep behavior disorder questionnaire was performed in an independent Parkinson’s disease cohort (n = 120). GBA mutations carriers had an OR of 6.24 (10.2% in patients vs. 1.8% in controls, P < 0.0001) for rapid eye movement sleep behavior disorder, and among Parkinson’s disease patients, the OR for mutation carriers to have probable rapid eye movement sleep behavior disorder was 3.13 (P = 0.039). These results demonstrate that rapid eye movement sleep behavior disorder is associated with GBA mutations, and that combining genetic and prodromal data may assist in identifying individuals susceptible to Parkinson’s disease

PEDIA: prioritization of exome data by image analysis.

PURPOSE: Phenotype information is crucial for the interpretation of genomic variants. So far it has only been accessible for bioinformatics workflows after encoding into clinical terms by expert dysmorphologists. METHODS: Here, we introduce an approach driven by artificial intelligence that uses portrait photographs for the interpretation of clinical exome data. We measured the value added by computer-assisted image analysis to the diagnostic yield on a cohort consisting of 679 individuals with 105 different monogenic disorders. For each case in the cohort we compiled frontal photos, clinical features, and the disease-causing variants, and simulated multiple exomes of different ethnic backgrounds. RESULTS: The additional use of similarity scores from computer-assisted analysis of frontal photos improved the top 1 accuracy rate by more than 20-89% and the top 10 accuracy rate by more than 5-99% for the disease-causing gene. CONCLUSION: Image analysis by deep-learning algorithms can be used to quantify the phenotypic similarity (PP4 criterion of the American College of Medical Genetics and Genomics guidelines) and to advance the performance of bioinformatics pipelines for exome analysis

EuReCa ONE—27 Nations, ONE Europe, ONE Registry A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe

AbstractIntroductionThe aim of the EuReCa ONE study was to determine the incidence, process, and outcome for out of hospital cardiac arrest (OHCA) throughout Europe.MethodsThis was an international, prospective, multi-centre one-month study. Patients who suffered an OHCA during October 2014 who were attended and/or treated by an Emergency Medical Service (EMS) were eligible for inclusion in the study. Data were extracted from national, regional or local registries.ResultsData on 10,682 confirmed OHCAs from 248 regions in 27 countries, covering an estimated population of 174 million. In 7146 (66%) cases, CPR was started by a bystander or by the EMS. The incidence of CPR attempts ranged from 19.0 to 104.0 per 100,000 population per year. 1735 had ROSC on arrival at hospital (25.2%), Overall, 662/6414 (10.3%) in all cases with CPR attempted survived for at least 30 days or to hospital discharge.ConclusionThe results of EuReCa ONE highlight that OHCA is still a major public health problem accounting for a substantial number of deaths in Europe.EuReCa ONE very clearly demonstrates marked differences in the processes for data collection and reported outcomes following OHCA all over Europe. Using these data and analyses, different countries, regions, systems, and concepts can benchmark themselves and may learn from each other to further improve survival following one of our major health care events

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Large expert-curated database for benchmarking document similarity detection in biomedical literature search

Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency-Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research.Peer reviewe

CD47 fusion protein targets CD172a+ cells in Crohn’s disease and dampens the production of IL-1β and TNF

In mice, the transfer of CD172a(+) (SIRP-α) dendritic cells (DCs) elicits T cell–driven colitis, whereas treatment with CD47-Fc protein, a CD172a-binding agent, confers protection. The aim of this study was to elucidate the nature and functional properties of human CD172a(+) DCs in chronic intestinal inflammation. Here, we show that CD172a(+)CD11c(+) cells accumulate in the mesenteric lymph nodes (mLNs) and inflamed intestinal mucosa in patients with Crohn’s disease (CD). These cells are distinct from resident DCs and may coexpress markers typically associated with monocyte-derived inflammatory DCs such as CD14 and/or DC-SIGN, E-Cadherin, and/or CX(3)CR1. Spontaneous IL-1β and TNF production by HLA-DR(+) cells in CD tissues is restricted to those expressing CD172a. An avidity-improved CD47 fusion protein (CD47-Var1) suppresses the release of a wide array of inflammatory cytokines by CD172a(+) cells, which may include HLA-DR(−)CD172a(+) neutrophils, in inflamed colonic explant cultures and impairs the ability of HLA-DR(+)CD172a(+) cells to activate memory Th17 but not Th1 responses in mLNs. In conclusion, targeting CD172a(+) cells may represent novel therapeutic perspectives for patients with CD

Synthèse et étude physico-chimique de nouveaux matériaux organiques d'électrode positive à base de phénothiazine pour les applications dans les accumulateurs au lithium

L objectif de cette thèse est de développer des matériaux organiques rédox à base de phénothiazine pour être utilisés à l électrode positive des batteries lithium. Les matériaux organiques s inscrivent en rupture des matériaux inorganiques coûteux et toxiques. Dans ce but, des matériaux rédox contenant l unité phénothiazine ont été synthétisés, caractérisés. Leurs propriétés électrochimiques ont été analysées par dépôt sur électrode et par microélectrode à cavité, puis les plus prometteurs ont été testés en cellule lithium et sodium. La cible rédox choisie, la phénothiazine, a été polymérisée et substituée à un squelette phosphazène. Les tests en cellules ont mis en évidence la dissolution systématique du matériau et la nécessité d empêcher ce phénomène rédhibitoire pour l application batterie. Dans ce but, l utilisation de polymères insolubles et de copolymères dotés d une fonction post-réticulable ont permis d augmenter significativement la cyclabilité et les performances énergétiques des cellules lithium. De plus, l utilisation du sodium à l électrode négative et d anions peu lipophiles ont également permis de limiter cette contribution de dissolution. Une fonctionnalisation du carbone par la phénothiazine a également été investiguée par deux stratégies différentes. Dans les deux cas, un greffage a été réalisé avec succès. Les analyses électrochimiques ont permis de confirmer des propriétés électrochimiques très prometteuses de ces carbones modifiés.The aim of this work is to develop phenothiazine-based redox organic materials for lithium positive electrode. Comparatively to inorganic materials, organic ones can constitute clear break by decreasing the cost, toxicity and security issues while keeping good performances. In that purpose, redox materials involving phenothiazine moieties have been synthesized, characterized, then, their electrochemical properties have been analyzed electrochemically, the most promising ones have been tested in lithium and sodium cells. The redox target chosen, the phenothiazine, has been polymerized and functionalized onto phosphazene backbone. Cell tests showed material dissolution contribution has to be avoided. In this context, insoluble polyphenothiazine and cross-linkable copolymers were able to upgrade significantly the cyclability and the energetic performances of lithium cells. Moreover, sodium cells with a poor lipophilic anion showed lower dissolution contribution. Carbon grafting by phenothiazine has also been investigated. It has been performed by electrochemical and chemical means and has led to promising electrochemical performances.SAVOIE-SCD - Bib.électronique (730659901) / SudocGRENOBLE1/INP-Bib.électronique (384210012) / SudocGRENOBLE2/3-Bib.électronique (384219901) / SudocSudocFranceF

Cerebral amyloid angiopathy with focal presentation—about 3 cases: none

International audienc

Cognitive and behavioural post-traumatic impairments: What is the specificity of a brain injury ? A study within the ESPARR cohort

Objectif : La diversité et l'étendue des déficits observés après un traumatisme crânien varient suivant la nature des lésions et leur gravité. Afin de mieux comprendre les interactions et leurs conséquences à long terme, nous avons étudié et comparé le profil cognitif et neurocomportemental d’une cohorte de victimes d’accidents de la voie publique avec ou sans traumatisme crânien, un an après l'accident. Méthode : La population d’étude est constituée de 207 blessés graves de La cohorte ESPARR. Cette cohorte de 1168 accidentés de la route dans le Rhône âgés de 16 ans et plus, et de toute gravité inclus selon critères : résidant dans le Rhône, victime d'un accident de la circulation impliquant au moins un véhicule à roues, ayant eu lieu dans le Rhône, vivant au moment de son arrivée à l'hôpital, et se présentant dans l'un des différents services d'urgences du Rhône. La représentativité de cette cohorte en termes de critères sociogéographiques et de caractéristiques de l'accident a été assurée par la nature spécifique du recrutement. Les plaintes et déficiences cognitivo-comportementales ont été évaluées un an après l’accident avec la Neurobehavioral Rating Scale-Revised et le Trail-Making-Test. Nous avons distingué, dans notre population d'étude de blessés graves, trois catégories de patients : les traumatisés crâniens modérés/graves (n=48), les traumatisés crâniens légers (n=89) et les blessés graves sans traumatisme crânien (n=70), basés sur le score de Glasgow, la présence de signes de déficits neurologiques, d'une aggravation de l'état neurologique dans les 72 heures et/ou d'une imagerie anormale. Résultats : Les symptômes les plus fréquemment observés étaient l’anxiété, l’irritabilité, les troubles mnésiques et attentionnels, la dépression et la labilité de l’humeur. L’humeur dépressive et l’irritabilité sont relevées aussi fréquemment dans les trois groupes. Les troubles de mémoire, d’attention, l’anxiété et la diminution des initiatives sont plus spécifiques au traumatisme crânien et les troubles exécutifs sont typiques d’un traumatisme crânien modéré/grave. Discussion-conclusion : La présence et la sévérité initiale du TC conditionnent la nature et la fréquence des séquelles à un an d’évolution. Certains troubles comme l'irritabilité, habituellement associée à un traumatisme crânien, n'apparaissent pas comme spécifiques à cette population, tout comme l'humeur dépressive. Ainsi, les interactions entre troubles cognitifs, émotivo-affectifs et neuro-comportementaux sont mises en avant